Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;61(4):436-448.
doi: 10.1002/mus.26782. Epub 2019 Dec 28.

Emery-Dreifuss muscular dystrophy

Affiliations
Review

Emery-Dreifuss muscular dystrophy

Scott A Heller et al. Muscle Nerve. 2020 Apr.

Abstract

Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications. EDMD classically presents with muscle weakness, early contractures, cardiac conduction abnormalities and cardiomyopathy, although the presence and severity of these manifestations vary by subtype and individual. Associated genes include EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43, SUN1, SUN2, and TTN, encoding emerin, lamin A/C, nesprin-1, nesprin-2, FHL1, LUMA, SUN1, SUN2, and titin, respectively. The Online Mendelian Inheritance in Man database recognizes subtypes 1 through 7, which captures most but not all of the associated genes. Genetic diagnosis is essential whenever available, but traditional diagnostic tools can help steer the evaluation toward EDMD and assist with interpretation of equivocal genetic test results. Management is primarily supportive, but it is important to monitor patients closely, especially for potential cardiac complications. There is a high potential for progress in the treatment of EDMD in the coming years.

Keywords: Emery-Dreifuss; cardiomyopathy; contractures; emerin; laminopathy; muscular dystrophy.

PubMed Disclaimer

Conflict of interest statement

Scott A. Heller has no conflicts of interest to disclose. Peter B. Kang has served as a consultant for AveXis and ChromaDex. He has served on an advisory board for Sarepta Therapeutics. He has received honoraria from Wiley for serving as an associate editor for Muscle & Nerve and from Wolters Kluwer for contributing material to UpToDate.

Figures

Figure 1
Figure 1
Schematic diagram of nuclear membrane indicating locations of proteins known to be associated with EDMD. Known protein interactions are shown (Courtesy Raghav Kalra)

References

    1. Cestan R, Lajonne NJ. Dystrophie musculaire. Iconogr Salpetriere. 1902;155:35.
    1. Becker PE, Kiener F. A new x‐chromosomal muscular dystrophy. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1955;193(4):427‐448. - PubMed
    1. Emery AE, Dreifuss FE. Unusual type of benign x‐linked muscular dystrophy. J Neurol Neurosurg Psychiatry. 1966;29(4):338‐342. - PMC - PubMed
    1. Rowland LP, Fetell M, Olarte M, Hays A, Singh N, Wanat FE. Emery‐Dreifuss muscular dystrophy. Ann Neurol. 1979;5(2):111‐117. - PubMed
    1. Mah JK, Korngut L, Fiest KM, et al. A systematic review and meta‐analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43(1):163‐177. - PubMed

Publication types

MeSH terms